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Objective: To investigate the eect of L-dopa on the PLM/h index of spinal cord injured
subjects.
Setting: Sa˜o Paulo, Brazil.
Methods: Thirteen male volunteers with spinal cord section between T7 –T12, and mean age
of 31.6+8.3 years participated in the study. L-dopa or placebo were administered for 30 days,
1 h before the volunteers went to sleep, in a double blind, crossover design. Polysomnographic
recordings were performed on ten occasions: Phase 1: Basal night, following an adaptation
night at the sleep laboratory; phase 2: after 1, 7, 21 and 30 days of L-dopa administration;
phase 3: first night of L-dopa or placebo withdrawal; phase IV: 1, 7, 21 and 30 days after
placebo ingestion.
Results: The index of PLM/h on the first night of L-dopa or placebo withdrawal (phase III)
was lower than on both the basal night and the first night of L-dopa treatment. At the time of
polysomnographic analysis, volunteers were divided into two groups: index of PLM/h below
five and those whose index was above five. Comparison between L-dopa and placebo
treatments revealed that only those volunteers with an index above five revealed a reduction in
PLM in L-dopa.
Conclusion: These results indicate that despite the spinal cord lesions, L-dopa treatment is
capable of minimizing PLM during sleep.
Keywords: sleep; spinal cord lesion(s); L-dopa; periodic leg movements (PLM); paraplegic;
restless legs syndrome (RLS)
Introduction
The restless legs syndrome (RLS) was originally
described in the general population by Ekbom.1
Later, an association between RLS and periodic leg
movements (PLM) was reported.2,21 These disturbances
may result in decreased sleep eciency and sleep
quality. A relation between dopaminergic deficit and
PLM/RLS3 as well as a reduction of dopaminergic D2
receptors in the basal ganglia of patients with PLM has
been described.4
Several studies have reported favourable results of
treatment of PLM with dopaminergic agonists.5 – 7
There is, however, a lack of consensus regarding
dosage and length of administration of these drugs
with therapeutic doses ranging between 100 and
250 mg of L-dopa.
Recently, a high incidence of PLM and RLS in
subjects with spinal cord lesions have been re-
ported,8 – 12 allowing the possibility of identifying the
origin of these abnormal movements. These subjects
spontaneously report sleep problems, and also even
mention the need to be tied to the bed so as to avoid
falling on the floor due to the frequency of lower
limb movements during sleep.9 Moreover, reduction
of the incidence of PLM and RLS following acute
physical activity in these patients may be helpful for
the identification of the mechanisms underlying PLM
and RLS.10,13 Thus, it is possible that the reduction
of limb movements may stem from endorphin
secretion induced by physical activity,14 since treat-
ment with opiates often results in a reduction of PLM
and RLS.3 In addition, there is an important positive
correlation between PLM and K complexes in spinal
cord injured10,11 and non-paraplegic subjects.3 To our
knowledge, there is no study of PLM in spinal cord
lesioned subjects treated with dopaminergic agonists.
It is known that dopamine plays an important role
in motor activity in general. Demonstrably, dopami-
nergic agonists induce a decrease in motor activity.
Tufik15 highlighted the reduction in motor activity
following administration of dopaminergic agonists in
REM sleep deprived rats. Andrade16 reported the role
played by dopamine on the pathophysiology of
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abnormal movements in Parkinsonian patients. Dopa-
minergic agonists have since been used in the
treatment of movement disorders.
Maitra17 observed the involvement of the spinal cord
in the pathophysiology of extrapyramidal motor
disorders. There are motor nerve terminals containing
muscarinic as well as inhibitory dopaminergic receptors
that influence acetylcholine release at the spinal cord
level.18 In order to study the inhibitory influence of the
dopaminergic system on spinal cholinergic transmis-
sion, Maitra17 used a monosynaptic excitatory pathway
from the collateral a motor axon of the Renshaw cells
using apomorphine (a dopaminergic agonist) and
sulpiride (a D2 dopaminergic antagonist). Based on
their findings, the authors concluded that dopamine
inhibited motor activity and influenced central acet-
ylcholine transmission. We may conclude that dopami-
nergic receptors are clearly involved in the central
modulation of cholinergic transmission originating in
the collateral a motor axon of the Renshaw cells.
We therefore decided to test the hypothesis that
abnormal movements in paraplegic subjects (PLM)
have a similar origin to PLM found in non-paraplegic
subjects. To this end, we treated such patients with L-
dopa (200 mg) associated to 50 mg to benzerazide
(peripheral dopaminergic antagonist) as an attempt to
observe only the central eects of this medication on
PLM/h indices in this specific population.
Methods
Thirteen male volunteers (mean age=31.6+8.3 years),
with complete spinal cord lesion, between T7 and T12,
were selected following contact through associations
for the disabled in the state of Sa˜o Paulo, Brazil. The
subjects were submitted to clinical/neurological and
neuroimaging evaluation to confirm the diagnosis.
L-Dopa (200 mg), in assocation with benzerazide
chloride (50 mg), or placebo was administered for 30
days, 1 h prior to sleep time. This period of drug
administration was followed by a 15-day period of
washout, in a double-blind, crossover design. The
subjects were divided into two groups, Group 1
receiving placebo whilst Group 2 were administered
L-dopa (200 mg) associated to Benzerazide (50 mg).
Polysomnographic (PSG) data (total of 130 record-
ings) were obtained in the following manner: Phase
1A: basal PSG; Phase 2A: PSG in 1, 7, 21 and 30
days; Phase 3A: PSG day 1 after drug or placebo
withdrawal; Phase 1B: after 15 days of washout
(second basal PSG for readaptation); Phase 2B: PSG
1, 7, 21 and 30 days; Phase 3B: PSG day 1 after
drug or placebo withdrawal. In accordance with the
crossover design, all volunteers received L-dopa
(200 mg) associated to benzerazide (50 mg) and
placebo.
Volunteers slept on two consecutive nights for basal
evaluation in which the first night served as an
adaptation night. Polysomnographic recordings were
taken on the second night.
There was a similar second adaptation (readap-
tation) in the period preceding phase IIB as volunteers
had spent 15 days away from the environment of our
sleep laboratory.
Polysomnography was performed according to
Rechtschaen and Kales19 and electrode placement
was carried out according to the 10 – 20 system.20
Recordings were obtained using the Oxford/Medilog
system (12 channels), with three channels for EEG,
three channels for EMG (two on the legs and one on
the chin), two channels for EOG, one channel for
ECG, one channel for airflow, and two channels for
abdominal and thoracic respiratory movements.
According to criteria established by ASDA,
pathological indices for PLM are above five move-
ments per hour, in non paraplegic patients. To this
end, in order to analyze our results, we decided to split
the subjects into two groups. (Group 1) those with less
than five movements per hour; (Group 2) those
displaying more than five movements per hour.21
The Kolmorogov-Smirnov test was used to evaluate
the normal distribution of the samples. Data was
subsequently analyzed using the Kruskal-Wallis test,
followed by the Friedman ANOVA and the Kendall
coecient of concordance test to compare the sleep
parameters of groups 1 (45 PLM/h) and 2 (45 PLM/
h) under drug and placebo treatments. The Wilcoxon
matched pair test was used to compare withdrawal
night (phases 3A+B) with basal night (phases 1A+B),
with first night of drug administration (phase 2A+B),
and with the first night of placebo administration.
Comparison of total arousal among recordings of
basal 1st, 7th, 21st, 30th nights of L-dopa treatment
was performed by the paired Student’s t-test.
Comparison among treatment nights and the corre-
sponding placebo nights was performed by the
Student’s t-test for independent samples. Arousal was
considered when the event was longer than 3 s,
according to the criteria established by the American
Sleep Disorders Association.22 Volunteers followed a
specified dietary regime on the lines recommended for
the entire duration of the study.23
Results
Despite a progressive decline of PLM absolute values
throughout the period of L-dopa treatment, the
reduction of abnormal movements of the lower limbs
during sleep was not statistically significant in the
group as a whole (Table 1).
The Wilcoxon matched pairs test was used to
compare data from phase 3 (withdrawal) and data
from phases 1 (basal) and 2 (first night of L-dopa
administration). The analysis highlighted a significant
reduction of the PLM/h index (phase 36phase 1;
P50.01 and phase 36phase 2; P50.03).
When both groups 1 (index of PLM/h below five)
and 2 (index of PLM/h above five) were analyzed
separately, no statistical dierence between phases 2
(L-dopa) and 3 (withdrawal) was observed for group
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1. However, Group 2 revealed a significant reduction
of abnormal lower limb movements during L-dopa
administration (P50.006).
There were no statistical dierences on total number
of arousals, despite a PLM reduction induced by
treatment with L-dopa. In regard to the apnea/
hypopnea index, our sample presented indices within
the normal range.
Discussion
Lesions or injury of the spinal cord at the cervical,
thoracic or lumbar levels determine paraplegic or
tetraplegic conditions. Subjects bearing this kind of
lesion exhibit several sequelae such as decreased motor
activity, muscle atrophy, reduction and impairment of
metabolic and cardiac activity, as well as the decline of
physical capacity.23
In spinal cord injured (at the level of T7 –T12)
subjects, abnormal lower limb movements (PLM)
could be influenced by dopamine at the spinal
level.24,25 Consequently, the dopaminergic inhibitory
role on abnormal motor activity is impaired by the
spinal cord lesion, and might be restored by treatment
with L-dopa associated with benzerazide as suggested
by the above results. Another possible explanation for
the lack of reduction on the number of arousals might
be the occurrence of respiratory events during sleep.
Nonetheless, our volunteers presented an apnea/
hypopnea index within normal values, detected by
the airflow technique. Still, it is not possible to reject
the occurrence of altered upper airway resistance,
which might have maintained the high levels of
arousal. These data may also suggest that the arousal
mechanism associated with abnormal movements is
impaired in subjects bearing spinal cord lesion; with
the lack of sensitivity below the level of the lesion the
stimulus generated by the abnormal movements would
not be perceived and would not result in arousal. It is
not easy to explain how the transmission of an
excitatory stimulus (highly likely to be generated in
the basal ganglia) might produce movements below
the level of a complete spinal cord injury. Even more
surprising are the volunteers’ responses to the
treatment L-dopa+benzerazide. One hypothesis to
account for this imbalance may involve the main-
tenance of a monosynaptic pathway,17 capable of
regulating the transmission of dopaminergic stimuli.
Dopamine, by stimulating dopaminergic D2 receptors,
might inhibit central cholinergic transmission yielding
a neurochemical balance (excitatory/inhibitory) which
would prevent the occurrence of such abnormal
movements. In our group of paraplegic subjects with
complete spinal cord lesions, this monosynaptic
pathway may be compromised permitting the appear-
ance of such abnormal movements (PLM). Exogenous
L-dopa, seemingly, would reinstate this balance,
reducing abnormal movements of the lower limbs.
In the present study, L-dopa was administered 1 h
before bed time, which might have resulted in a
possible drop in the compound’s concentration during
the final third of the night, thus reducing the drug’s
ecacy on the PLM index. The use of a controlled-
release L-dopa could be a useful strategy in future
studies, in order to reduce this problem.
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